2.8700 +0.83 (40.69%)
Pre-Market: 7:24AM EST
|Bid||3.5300 x 800|
|Ask||3.4100 x 1300|
|Day's Range||1.5290 - 2.1000|
|52 Week Range||0.9200 - 29.6000|
|Beta (5Y Monthly)||0.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2020 - Mar 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.50|
OpGen, Inc. (OPGN) reported an update on the business of Curetis GmbH (“Curetis”), the other party to the planned business combination with OpGen. Today, Curetis announced preliminary, unaudited 2019 condensed combined key financials and provided a business update. Revenue growth in 2019 was primarily driven by partnering projects of Curetis Group Company Ares Genetics as well as increasing uptake of Curetis’ Unyvero product line.
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that total revenue for 2019 increased 18.7% to $3.5 million, up from $3.0 million in 2018. OpGen working interactively with the FDA to provide final responses to Additional Information Request Letters for the Acuitas AMR Gene Panel (Isolates) pending FDA 510(K) submission.
BGI Group responds to coronavirus crisis by providing reagent kits for molecular 2019-nCoV testing by next-generation sequencing and RT-PCRAres Genetics to launch.
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that a key milestone has been accomplished in the proposed business combination with Curetis, N.V. (Euronext: CURE, “Curetis”), a developer of next-level molecular diagnostic solutions. On January 27, 2020, OpGen filed and furnished to its stockholders a proxy statement/prospectus and a notice of special meeting of OpGen stockholders, to be held on March 10, 2020 at 10:00am ET at the offices of Ballard Spahr LLP, 1909 K Street, NW, 12 th Floor, Washington DC.
- Clearance expected to substantially increase total addressable market for Unyvero System in the U.S. GAITHERSBURG, Md., Dec. 23, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (OPGN) reported an update on the business of Curetis GmbH (“Curetis”), the other party to the planned business combination with OpGen. On December 20, 2019 Curetis announced that the Company has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market its Unyvero LRT Lower Respiratory Tract Application Cartridge for use with bronchoalveolar lavage (BAL) samples to diagnose lower respiratory tract infections such as pneumonia.
Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo
OpGen, Inc. (OPGN) today provided a business update for the Curetis Group and announced that key milestones in the planned business combination have been achieved. Curetis recently announced that it has filed its formal response to the FDA’s Additional Information Request letter regarding Curetis’ filing for 510(k) clearance of the Unyvero LRT – Lower Respiratory Tract Application Cartridge for bronchoalveolar lavage (BAL) samples. Curetis now expects a near term clearance decision.
OpGen, Inc. (OPGN) announced today that the Center for Disease Control (CDC) has released updated data increasing the number of deaths in the United States (U.S.) from antibiotic-resistant bacteria and fungi, and highlighting the continuing threat of rising antibiotic resistance. According to the CDC, these pathogens cause more than 2.8 million infections and 35,000 deaths in the U.S. each year.
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -28.46% and -28.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
22% Revenue Increase Year-to-Date Update on Announced Agreement to Combine Business with Curetis Conference call to be held at 4:30 p.m. Eastern Time today GAITHERSBURG, Md.,.
OpGen, Inc. (OPGN) reported an update on the business of Curetis GmbH, the other party to the planned business combination with OpGen. On October 28, 2019, Curetis, N.V. announced that its wholly-owned subsidiary Ares Genetics GmbH (“Ares Genetics”) has launched an early access program for its novel, artificial intelligence (AI) powered, next-generation sequencing (NGS) based molecular antibiotic susceptibility test (AST).
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GAITHERSBURG, Md., Oct. 29, 2019 -- OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its third quarter 2019 financial results after the close of the U.S..
OpGen, Inc. (OPGN) today announced the closing of its previously announced underwritten public offering of 2,590,170 units at $2.00 per unit and 2,109,830 pre-funded units at $1.99 per pre-funded unit, raising gross proceeds of approximately $9.4 million, prior to deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriter a 30-day option to purchase up to an additional 705,000 shares of common stock and/or common warrants to purchase up to 705,000 shares of common stock.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) AVITA ...
OpGen, Inc. (OPGN) today announced the pricing of an underwritten offering of an aggregate of 4,700,000 units at an effective price of $2.00 per unit. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share of common stock. OpGen expects to receive aggregate gross proceeds of $9.4 million from the offering, prior to deducting underwriting discounts and commissions and other estimated offering expenses.
OpGen, Inc. (OPGN) announced today that the United States Patent and Trademark Office (the “USPTO”) has allowed a key OpGen patent covering the Lighthouse Profiling technology used in the company’s software for tracking antimicrobial resistant pathogens. Patent application US 20160085912A1 “Systems, Apparatus, and Methods for Generating and Analyzing Resistome Profiles” covers the use of the company’s Acuitas Lighthouse® Software for real-time monitoring of superbug infections and other multi-drug resistant infections. The Lighthouse Software was developed for use with the Acuitas® AMR Gene Panel for testing bacterial isolates.
The data demonstrate the concordance of Acuitas AMR Gene Panel results with conventional urine culture and the agreement with whole genome sequencing for the detection of a broad set of resistance genes that span nine antibiotic classes. Data showing antibiotic resistance predictive alignment with antibiotic susceptibility testing were also presented at the meeting.
OpGen’s Director of Clinical Laboratory, Dr. Jamie Lemon, Ph.D., D(ABMM), will present during the session “Rapid Diagnostics and Resistance: Making Sense of Now and the Future Part 2,” which will occur in Ballroom ABC on Saturday, October 5 from 8:00AM ET - 9:00AM ET. Dr. Lemon’s portion of the program will focus on OpGen’s Acuitas AMR Gene Panel and Acuitas Lighthouse Software, proprietary solutions in development which combine the power of genomics and informatics to inform antibiotic decision-making.
Curetis R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdbCollaborator to fund R&D and obtains option to license ARESdb.